FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Shaker Mousa

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Mouse

Disorders

Co-author Network

Publications

TOP 3
Murat Yalcin; Steven C Stain; Thangirala Sudha; Heng-Yuan Tang; Dhruba J Bharali; Faith B Davis; Paul J Davis; Hung-Yun Lin; Ran Meng; Shaker A Mousa
Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic Acid nanoparticles.
Abdelhadi Rebbaa; Thangirala Sudha; Murat Yalcin; Ghanshyam Patil; Shaker A Mousa
OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis.
Manjunath P Pai; Barbara Zaffo; Wen Zhen Chen; Huadong Cui; Hassan A N El-Fawal; Adinoyi Garba; Shaker A Mousa
Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Shaker Mousa (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Murat Yalcin; Steven C Stain; Thangirala Sudha; Heng-Yuan Tang; Dhruba J Bharali; Faith B Davis; Paul J Davis; Hung-Yun Lin; Ran Meng; Shaker A Mousa
Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic Acid nanoparticles.
Hormones & cancer 2013;4(3):176-85.
2013: Abdelhadi Rebbaa; Thangirala Sudha; Murat Yalcin; Ghanshyam Patil; Shaker A Mousa
OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis.
Cancer letters 2013;332(1):55-62.
2013: Manjunath P Pai; Barbara Zaffo; Wen Zhen Chen; Huadong Cui; Hassan A N El-Fawal; Adinoyi Garba; Shaker A Mousa
Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model.
Antimicrobial agents and chemotherapy 2013;57(2):716-22.
2013: Paul J Davis; Gennadi V Glinsky; Aleck Hercbergs; Sandra Incerpi; Hung-Yun Lin; Shaker A Mousa; Heng Yuan Tang; Faith B Davis; Mary K Luidens
Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response.
Endocrine research 2013;38(2):112-8.
2013: Michael Thomas; Shaymaa S Mousa; Shaker A Mousa
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.
Clinical ophthalmology (Auckland, N.Z.) 2013;7():495-501.
2013: Shaker A Mousa
Comparative pharmacodynamic assessment of the antiangiogenesis activity of heparin and low-molecular-weight heparin fractions: structure-function relationship.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2013;19(1):48-54.
2012: Clinton W Yang; Shaker A Mousa
The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders.
Complementary therapies in medicine 2012;20(6):466-74.
2012: Jamil Stanekzai; Esma R Isenovic; Shaker A Mousa
Treatment options for diabetes: potential role of stem cells.
Diabetes research and clinical practice 2012;98(3):361-8.
2012: Mohammed Salleh M Ardawi; Nawal S Al-Senani; Sharifa A Al-Sibiani; Mohammed H Qari; Abdulrahim A Rouzi; Shaker A Mousa
High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2012;27(12):2592-602.
2012: Robert C Block; J Thomas Brenna; Pedro CalderonArtero; Matthew Jonovich; Lisa Kakinami; Peter Lawrence; Nida Meednu; Shaker A Mousa; Illena Antonetti; Steve N Georas
The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans.
Prostaglandins, leukotrienes, and essential fatty acids 2012;87(4-5):143-51.
2012: Shaker A Mousa
The future of anticoagulant therapy.
Cardiovascular therapeutics 2012;30(5):255-6.
2012: Hung-Yun Lin; Mary K Luidens; Ran Meng; Shaker A Mousa; Heng Yuan Tang; Faith B Davis; Sandra Incerpi; Paul J Davis
Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps.
Discovery medicine 2012;14(76):199-206.
2012: Thangirala Sudha; Patricia Phillips; Lubor Borsig; Camille Kanaan; Robert J Linhardt; Shaker A Mousa
Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Clinical & experimental metastasis 2012;29(5):431-9.
2012: Shaker A Mousa; Heng-Yuan Tang; Murat Yalcin; Dhruba J Bharali; Faith B Davis; Hung-Yun Lin; Ran Meng; Paul J Davis
Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts.
Lung cancer (Amsterdam, Netherlands) 2012;76(1):39-45.
2012: Mohammed H Qari; U Dier; Shaker A Mousa
Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2012;18(2):195-200.
2012: S Pabani; Shaker A Mousa
Current and future treatment of pulmonary hypertension.
Drugs of today (Barcelona, Spain : 1998) 2012;48(2):133-47.
2012: Nathan J Rogers; Shaker A Mousa
The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome.
Journal of alternative and complementary medicine (New York, N.Y.) 2012;18(2):112-9.
2012: Gabriel Beidoe; Shaker A Mousa
Current primary open-angle glaucoma treatments and future directions.
Clinical ophthalmology (Auckland, N.Z.) 2012;6():1699-707.
2012: Melamangalam S Jayaraman; Dhruba J Bharali; Thangirala Sudha; Shaker A Mousa
Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration.
Molecular vision 2012;18():2300-8.
2012: Wosen Aman; Shaymaa Mousa; Gamal Shiha; Shaker A Mousa
Current status and future directions in the management of chronic hepatitis C.
Virology journal 2012;9():57.
2012: Danielle Swanson; Robert Block; Shaker A Mousa
Omega-3 fatty acids EPA and DHA: health benefits throughout life.
Advances in nutrition (Bethesda, Md.) 2012;3(1):1-7.
2011: Alexandre Bridoux; Celei Chen; Gwenaël Chevé; Huadong Cui; Evgeny Dyskin; Riaz A Khan; Aziz Yasri; Shaker A Mousa
Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: new anti-angiogenesis analogs.
Journal of enzyme inhibition and medicinal chemistry 2011;26(6):871-82.
2011: Mohamed Haidara; Branislava Dobutovic; Dimitri P Mikhailidis; Shaker A Mousa; Manfredi Rizzo; Katarina T Smiljanic; Sanja Soskic; Hanaa Z Yassin; Esma R Isenovic
Evaluation of the possible contribution of antioxidants administration in metabolic syndrome.
Current pharmaceutical design 2011;17(33):3699-712.
2011: Yongmei Xu; Juliana Jing; Robert J Linhardt; Renpeng Liu; Sayaka Masuko; Shaker A Mousa; Majde Takieddin; Haoming Xu; Jian Liu
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins.
Science (New York, N.Y.) 2011;334(6055):498-501.
2011: Abdulqader Alhaidar; Abdel-Galil M Abdel Gader; Shaker A Mousa
The antiplatelet activity of camel urine.
Journal of alternative and complementary medicine (New York, N.Y.) 2011;17(9):803-8.
2011: Bo Yang; Amanda Weyers; Jong Youn Baik; Eric Sterner; Susan Sharfstein; Shaker A Mousa; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis.
Analytical biochemistry 2011;415(1):59-66.
2011: Paul J Davis; Aleck A Hercbergs; Hung-Yun Lin; Mary K Luidens; Shaker A Mousa; Martin Wehling; Faith B Davis
Overlapping nongenomic and genomic actions of thyroid hormone and steroids.
Steroids 2011;76(9):829-33.
2011: David Laurenzo; Shaker A Mousa
Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing.
Acta tropica 2011;119(1):5-10.
2011: Hung-Yun Lin; Vivian Cody; Faith B Davis; Aleck A Hercbergs; Mary K Luidens; Shaker A Mousa; Paul J Davis
Identification and functions of the plasma membrane receptor for thyroid hormone analogues.
Discovery medicine 2011;11(59):337-47.
2011: Patricia G Phillips; Murat Yalcin; Huadong Cui; Hani Abdel-Nabi; Munawwar Sajjad; Ralph Bernacki; Jean Veith; Shaker A Mousa
Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin.
Anticancer research 2011;31(2):411-9.
2011: Ran Meng; Shaker A Mousa; Heng-Yuan Tang; Jennifer Westfall; James H Cao; Faith B Davis; Paul J Davis; Aleck Hercbergs; David London; Mary Luidens; Hung-Yun Lin
Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells.
PloS one 2011;6(11):e27547.
2011: Hung-Yun Lin; Mary K Luidens; Shaker A Mousa; Min Zhou; James H Cao; Faith B Davis; Paul J Davis
Molecular basis for certain neuroprotective effects of thyroid hormone.
Frontiers in molecular neuroscience 2011;4():29.
2011: Joseph Ramli; Robert C Block; Pedro CalderonArtero; Shaker A Mousa
Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease.
Cardiology journal 2011;18(4):352-63.
2011: Stephanie Clayton; Shaker A Mousa
Therapeutics formulated to target cancer stem cells: Is it in our future?
Cancer cell international 2011;11():7.
2011: Hung-Yun Lin; Cornelia Landersdorfer; David London; Ran Meng; Chang-Uk Lim; Cassie Lin; Sharon Lin; Heng-Yuan Tang; David Brown; Brian Van Scoy; Robert Kulawy; Lurdes Queimado; George L Drusano; Arnold Louie; Faith B Davis; Shaker A Mousa; Paul J Davis
Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system.
PLoS computational biology 2011;7(2):e1001073.
2011: Paul J Davis; Faith B Davis; Shaker A Mousa; Mary K Luidens; Hung-Yun Lin
Membrane receptor for thyroid hormone: physiologic and pharmacologic implications.
Annual review of pharmacology and toxicology 2011;51():99-115.
2010: Dhruba J Bharali; Shaker A Mousa
Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Pharmacology & therapeutics 2010;128(2):324-35.
2010: Ahmad Aljada; Lynn Dong; Shaker A Mousa
Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications.
Current opinion in investigational drugs (London, England : 2000) 2010;11(10):1158-68.
2010: Olapeju G Aderinwale; Hans W Ernst; Shaker A Mousa
Current therapies and new strategies for the management of Alzheimer's disease.
American journal of Alzheimer's disease and other dementias 2010;25(5):414-24.
2010: Shaker A Mousa; Abbdulkareem Al Momen; Faisal Al Sayegh; Soad Al Jaouni; Zaki Nasrullah; Hussein Al Saeed; Abbas Alabdullatif; Mohamad Al Sayegh; Hazaa Al Zahrani; Maha Hegazi; Amin Al Mohamadi; A Alsulaiman; Awad Omer; Salam Al Kindi; Ahamd Tarawa; Fahad Al Othman; mohamad qari
Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010;16(4):365-76.
2010: Alexandre Bridoux; Huadong Cui; Evgeny Dyskin; Andreea-Ruxandra Schmitzer; Murat Yalcin; Shaker A Mousa
Semisynthesis and pharmacological activities of thyroxine analogs: Development of new angiogenesis modulators.
Bioorganic & medicinal chemistry letters 2010;20(11):3394-8.
2010: Shaker A Mousa; Shaymaa S Mousa
Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2010;24(3):183-94.
2010: Shaymaa S Mousa; Faith B Davis; Paul J Davis; Shaker A Mousa
Human platelet aggregation and degranulation is induced in vitro by L-thyroxine, but not by 3,5,3'-triiodo-L-thyronine or diiodothyropropionic acid (DITPA).
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010;16(3):288-93.
2010: Owoedimo B Usoro; Shaker A Mousa
Vitamin E forms in Alzheimer's disease: a review of controversial and clinical experiences.
Critical reviews in food science and nutrition 2010;50(5):414-9.
2010: Shaker A Mousa; Walter P Jeske; Jawed Fareed
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010;16(2):170-6.
2010: Murat Yalcin; E Dyskin; L Lansing; Dhruba J Bharali; S S Mousa; A Bridoux; A H Hercbergs; H Y Lin; Faith B Davis; Gennadi V Glinsky; A Glinskii; J Ma; Paul J Davis; Shaker A Mousa
Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid.
The Journal of clinical endocrinology and metabolism 2010;95(4):1972-80.
2010: Shaker A Mousa; Thangirala Sudha; Evgeny Dyskin; Usawadee Dier; Christine Gallati; Christine Hanko; Sridar V Chittur; Abdelhadi Rebbaa
Stress resistant human embryonic stem cells as a potential source for the identification of novel cancer stem cell markers.
Cancer letters 2010;289(2):208-16.
2010: Murat Yalcin; Dhruba J Bharali; Evgeny Dyskin; Emmy Dier; Lawrence Lansing; Shaymaa S Mousa; Faith B Davis; Paul J Davis; Shaker A Mousa
Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma.
Thyroid : official journal of the American Thyroid Association 2010;20(3):281-6.
2010: Mary K Luidens; Shaker A Mousa; Faith B Davis; Hung-Yun Lin; Paul J Davis
Thyroid hormone and angiogenesis.
Vascular pharmacology 2010;52(3-4):142-5.
2010: Paul J Davis; Min Zhou; Faith B Davis; Lawrence Lansing; Shaker A Mousa; Hung-Yun Lin
Mini-review: Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells.
Physiology & behavior 2010;99(2):237-9.
2010: Sarah Rofaiel; Esther N Muo; Shaker A Mousa
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management.
Pharmacogenomics and personalized medicine 2010;3():129-43.
2010: Whitney P Caron; Shaker A Mousa
Prevention strategies for antimicrobial resistance: a systematic review of the literature.
Infection and drug resistance 2010;3():25-33.
2010: Shaker A Mousa; mohamad qari
Diagnosis and management of sickle cell disorders.
Methods in molecular biology (Clifton, N.J.) 2010;663():291-307.
2010: Shaker A Mousa
Pharmacogenomics in thrombosis.
Methods in molecular biology (Clifton, N.J.) 2010;663():277-89.
2010: Shaker A Mousa
Adhesion molecules: potential therapeutic and diagnostic implications.
Methods in molecular biology (Clifton, N.J.) 2010;663():261-76.
2010: Ali Amirkhosravi; Shaker A Mousa; Mildred Amaya; Todd Meyer; Monica Davila; Theresa Robson; John L Francis
Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis.
Methods in molecular biology (Clifton, N.J.) 2010;663():241-59.
2010: Shaker A Mousa
Antithrombotic effects of naturally derived products on coagulation and platelet function.
Methods in molecular biology (Clifton, N.J.) 2010;663():229-40.
2010: Shaker A Mousa; Walter P Jeske; Jawed Fareed
Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist.
Methods in molecular biology (Clifton, N.J.) 2010;663():221-8.
2010: Shaker A Mousa
Antiplatelet therapies: drug interactions in the management of vascular disorders.
Methods in molecular biology (Clifton, N.J.) 2010;663():203-19.
2010: Shaker A Mousa
Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
Methods in molecular biology (Clifton, N.J.) 2010;663():181-201.
2010: Shaker A Mousa
Novel anticoagulant therapy: principle and practice.
Methods in molecular biology (Clifton, N.J.) 2010;663():157-79.
2010: Shaker A Mousa
Heparin and low-molecular weight heparins in thrombosis and beyond.
Methods in molecular biology (Clifton, N.J.) 2010;663():109-32.
2010: Shaker A Mousa
In vivo models for the evaluation of antithrombotics and thrombolytics.
Methods in molecular biology (Clifton, N.J.) 2010;663():29-107.
2010: Shaker A Mousa
In vitro methods of evaluating antithrombotics and thrombolytics.
Methods in molecular biology (Clifton, N.J.) 2010;663():1-28.
2010: Yun Lin; Shaymaa S Mousa; Nabil Elshourbagy; Shaker A Mousa
Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.
Vascular health and risk management 2010;6():73-85.
2010: Douglas B Jacoby; Evgeny Dyskin; Murat Yalcin; Kamala Kesavan; William Dahlberg; Judson Ratliff; Eric W Johnson; Shaker A Mousa
Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide.
Anticancer research 2010;30(1):39-46.
2009: Safer Abdel-Majeed; Afzal Mohammad; Al-Bloushi Shaima; Rafique Mohammad; Shaker A Mousa
Inhibition property of green tea extract in relation to reserpine-induced ribosomal strips of rough endoplasmic reticulum (rER) of the rat kidney proximal tubule cells.
The Journal of toxicological sciences 2009;34(6):637-45.
2009: Oleksandra Katrych; Tessa M Simone; Shara Azad; Shaker A Mousa
Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.
CNS & neurological disorders drug targets 2009;8(6):512-9.
2009: Paul J Davis; Faith B Davis; Hung-Yun Lin; Shaker A Mousa; Min Zhou; Mary K Luidens
Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor.
American journal of physiology. Endocrinology and metabolism 2009;297(6):E1238-46.
2009: Melissa M Kemp; Ashavani Kumar; Shaymaa Mousa; Evgeny Dyskin; Murat Yalcin; Pulickel M Ajayan; Robert J Linhardt; Shaker A Mousa
Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties.
Nanotechnology 2009;20(45):455104.
2009: Abdelhadi Rebbaa; Fei Chu; Thangirala Sudha; Christine Gallati; Usawadee Dier; Evgeny Dyskin; Murat Yalcin; Christine Bianchini; Olfat Shaker; Shaker A Mousa
The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor.
Anticancer research 2009;29(11):4473-81.
2009: Anna B Glinskii; Gennadi V Glinsky; Hung-Yun Lin; Heng-Yuan Tang; Mingzeng Sun; Faith B Davis; Mary K Luidens; Shaker A Mousa; Aleck Hercbergs; Paul J Davis
Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac).
Cell cycle (Georgetown, Tex.) 2009;8(21):3554-62.
2009: Anhtung Duong; Shaker A Mousa
Current status of nucleoside antivirals in chronic hepatitis B.
Drugs of today (Barcelona, Spain : 1998) 2009;45(10):751-61.
2009: Shaker A Mousa; Lars J Petersen
Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.
Thrombosis and haemostasis 2009;102(2):258-67.
2009: Jiraporn Suwan; Zhenqing Zhang; Boyangzi Li; Preeyanat Vongchan; Puttinan Meepowpan; Fuming Zhang; Shaker A Mousa; Shaymaa Mousa; Bhusana Premanode; Prachya Kongtawelert; Robert J Linhardt
Sulfonation of papain-treated chitosan and its mechanism for anticoagulant activity.
Carbohydrate research 2009;344(10):1190-6.
2009: Hugo R Arias; Victoria E Richards; David Ng; Mary E Ghafoori; Vanique Le; Shaker A Mousa
Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis.
The international journal of biochemistry & cell biology 2009;41(7):1441-51.
2009: Justin LaRocque; Dhruba J Bharali; Shaker A Mousa
Cancer detection and treatment: the role of nanomedicines.
Molecular biotechnology 2009;42(3):358-66.
2009: Hung-Yun Lin; Paul J Davis; Heng-Yuan Tang; Shaker A Mousa; Mary K Luidens; Aleck H Hercbergs; Faith B Davis
The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone.
Cell cycle (Georgetown, Tex.) 2009;8(12):1877-82.
2009: Alexandre Bridoux; Huadong Cui; Evgeny Dyskin; Murat Yalcin; Shaker A Mousa
Semisynthesis and pharmacological activities of Tetrac analogs: angiogenesis modulators.
Bioorganic & medicinal chemistry letters 2009;19(12):3259-63.
2009: John W Martin; Shaymaa S Mousa; Olfat Shaker; Shaker A Mousa
The multiple faces of nicotine and its implications in tissue and wound repair.
Experimental dermatology 2009;18(6):497-505.
2009: Hung-Yun Lin; Mingzeng Sun; Heng-Yuan Tang; Cassie Lin; Mary K Luidens; Shaker A Mousa; Sandra Incerpi; George L Drusano; Faith B Davis; Paul J Davis
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
American journal of physiology. Cell physiology 2009;296(5):C980-91.
2009: Shaker A Mousa; Christine Gallati; Tessa Simone; Emmy Dier; Murat Yalcin; Evgeny Dyskin; Sudha Thangirala; Christine Hanko; Abdelhadi Rebbaa
Dual targeting of the antagonistic pathways mediated by Sirt1 and TXNIP as a putative approach to enhance the efficacy of anti-aging interventions.
Aging 2009;1(4):412-24.
2009: Melissa M Kemp; Ashavani Kumar; Shaymaa Mousa; Tae-Joon Park; Pulickel Ajayan; Natsuki Kubotera; Shaker A Mousa; Robert J Linhardt
Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities.
Biomacromolecules 2009;10(3):589-95.
2009: Imtiaz Siddiqui; Vaqar Adhami; Dhruba J Bharali; Bilal Bin Hafeez; Mohammad Asim; Sabih I Khwaja; Nihal Ahmad; Huadong Cui; Shaker A Mousa; Hasan Mukhtar
Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate.
Cancer research 2009;69(5):1712-6.
2009: Byung Chul Park; Su-Young Park; Jong-Suk Lee; Shaker A Mousa; Jong Tae Kim; Mi-Kyoung Kwak; Keon Wook Kang; Eung Seok Lee; Han-Gon Choi; Chul Soon Yong; Jung-Ae Kim
The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling.
Vascular pharmacology 2009;50(3-4):123-31.
2009: Kholood Alasfoor; Mona Alrasheed; Faisal Alsayegh; Shaker A Mousa
Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP).
Annals of hematology 2009;88(3):239-43.
2009: Faisal Alsayegh; Aisha Fakeir; Salah Alhumood; Kefaya Abdumalek; Hatem Matar; Isaac Samaul; Narayanan Nampoory; Housam Kabalawi; Shaker A Mousa
Use of recombinant activated factor VII to arrest uncontrolled bleeding: a case series.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(2):225-32.
2009: Shaima Al-Bloushi; AM Safer; Mohammed Afzal; Shaker A Mousa
Green tea modulates reserpine toxicity in animal models.
The Journal of toxicological sciences 2009;34(1):77-87.
2009: Hector Clarke; Shaker A Mousa
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent.
Pharmacogenomics and personalized medicine 2009;2():93-9.
2009: Peter Avery; Shaymaa S Mousa; Shaker A Mousa
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.
Pharmacogenomics and personalized medicine 2009;2():79-91.
2009: Robert Greene; Shaymaa S Mousa; Mohamed Ardawi; Mohamed Qari; Shaker A Mousa
Pharmacogenomics in osteoporosis: Steps toward personalized medicine.
Pharmacogenomics and personalized medicine 2009;2():69-78.
2009: Christopher Barone; Shaymaa S Mousa; Shaker A Mousa
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine.
Pharmacogenomics and personalized medicine 2009;2():59-67.
2009: Christine Brady; Shaymaa S Mousa; Shaker A Mousa
Polycystic ovary syndrome and its impact on women's quality of life: More than just an endocrine disorder.
Drug, healthcare and patient safety 2009;1():9-15.
2009: Paul J Davis; Faith B Davis; Shaker A Mousa
Thyroid hormone-induced angiogenesis.
Current cardiology reviews 2009;5(1):12-6.
2009: Khanh Tran; Robert M Levin; Shaker A Mousa
Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction.
Advances in urology 2009;():345324.
2009: Ahmad Aljada; Kshitij Ashwin Shah; Shaker A Mousa
Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?
PPAR research 2009;2009():460764.
2009: Faisal Alsayegh; Mona Al-Rasheed; Ali Al-Muhaini; Ekhlas Al-Humoud; Mona Al-Ostaz; Shaker A Mousa
Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study.
Cardiovascular therapeutics 2009;27(2):77-82.
2009: Dhruba J Bharali; Marianne Khalil; Mujgan Gurbuz; Tessa M Simone; Shaker A Mousa
Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers.
International journal of nanomedicine 2009;4():1-7.
2009: Xin Zheng; Fei Chu; Pauline M Chou; Christine Gallati; Usawadee Dier; Bernard L Mirkin; Shaker A Mousa; Abdelhadi Rebbaa
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism.
American journal of physiology. Cell physiology 2009;296(1):C65-74.
2008: Xin Zheng; Fei Chu; Bernard L Mirkin; Thangirala Sudha; Shaker A Mousa; Abdelhadi Rebbaa
Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy.
Biochimica et biophysica acta 2008;1783(12):2294-300.
2008: Willie E Bawarski; Elena Chidlowsky; Dhruba J Bharali; Shaker A Mousa
Emerging nanopharmaceuticals.
Nanomedicine : nanotechnology, biology, and medicine 2008;4(4):273-82.
2008: Dhruba J Bharali; Vandana Pradhan; Galina Elkin; Wu Qi; Alan Hutson; Shaker A Mousa; Yasmin Thanavala
Novel nanoparticles for the delivery of recombinant hepatitis B vaccine.
Nanomedicine : nanotechnology, biology, and medicine 2008;4(4):311-7.
2008: Tae-Joon Park; Sang-Hyun Lee; Trevor J Simmons; Jeffrey Martin; Shaker A Mousa; Elisaveta A Snezhkova; Veronika V Sarnatskaya; Vladimir G Nikolaev; Robert J Linhardt
Heparin-cellulose-charcoal composites for drug detoxification prepared using room temperature ionic liquids.
Chemical communications (Cambridge, England) 2008;(40):5022-4.
2008: Fei Chu; Pauline Chou; Bernard L Mirkin; Shaker A Mousa; Abdelhadi Rebbaa
Cellular conditioning with trichostatin A enhances the anti-stress response through up-regulation of HDAC4 and down-regulation of the IGF/Akt pathway.
Aging cell 2008;7(4):516-25.
2008: Rosemary J Santulli; William A Kinney; Shyamali Ghosh; Bart L Decorte; Li Liu; Robert W Tuman; Zhao Zhou; Norman Huebert; Sven E Bursell; Alan C Clermont; Maria B Grant; Lynn C Shaw; Shaker A Mousa; Robert Anthony Galemmo; Dana L Johnson; Bruce E Maryanoff; Bruce Damiano
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
The Journal of pharmacology and experimental therapeutics 2008;324(3):894-901.
2008: Ramez R Fares; Lawrence S Lansing; Christine A Gallati; Shaker A Mousa
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
Expert opinion on pharmacotherapy 2008;9(3):377-86.
2008: Edward Norey; Tessa M Simone; Shaker A Mousa
The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand.
Applied health economics and health policy 2008;6(2-3):93-102.
2008: Ahmad Aljada; Laura O'Connor; Yu-Yen Fu; Shaker A Mousa
PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis.
Angiogenesis 2008;11(4):361-7.
2008: Kimberly Ovsag; Sabrina Hydery; Shaker A Mousa
Preferred drug lists: potential impact on healthcare economics.
Vascular health and risk management 2008;4(2):403-13.
2008: Abdelhadi Rebbaa; Fei Chu; Faith B Davis; Paul J Davis; Shaker A Mousa
Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent.
Angiogenesis 2008;11(3):269-76.
2008: Shaker A Mousa
Cell adhesion molecules: potential therapeutic & diagnostic implications.
Molecular biotechnology 2008;38(1):33-40.
2008: Shaker A Mousa; Joel J Bergh; Emie Dier; Abdelhadi Rebbaa; Laura J O'Connor; Murat Yalcin; Ahmad Aljada; Evgeny Dyskin; Faith B Davis; Hung-Yung Lin; Paul J Davis
Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
Angiogenesis 2008;11(2):183-90.
2007: Shaker A Mousa; Fuming Zhang; Ahmad Aljada; Seema Chaturvedi; Majde Takieddin; Haifeng Zhang; Lianli Chi; M Cristina Castelli; Kristen Friedman; Michael M Goldberg; Robert J Linhardt
Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects.
Journal of clinical pharmacology 2007;47(12):1508-20.
2007: Ali Amirkhosravi; Todd Meyer; Mildred Amaya; Monica Davila; Shaker A Mousa; Theresa Robson; John L Francis
The role of tissue factor pathway inhibitor in tumor growth and metastasis.
Seminars in thrombosis and hemostasis 2007;33(7):643-52.
2007: John A Powell; Shaker A Mousa
Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis.
Journal of cellular biochemistry 2007;102(2):412-20.
2007: Shaker A Mousa; Dhruba J Bharali; Donald Armstrong
From nutraceuticals to pharmaceuticals to nanopharmaceuticals: a case study in angiogenesis modulation during oxidative stress.
Molecular biotechnology 2007;37(1):72-80.
2007: mohamad qari; Soad Khalil Aljaouni; Mohamad Salleh Alardawi; Huda Fatani; Fatin Mohamad Alsayes; Panagiotis Zografos; Mohamad Alsaigh; Adnan Alalfi; Mohamad Alamin; Abdulilah Gadi; Shaker A Mousa
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial.
Thrombosis and haemostasis 2007;98(2):392-6.
2007: Shaker A Mousa
Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links.
Seminars in thrombosis and hemostasis 2007;33(5):524-33.
2007: Melissa E Cloonan; Marianne DiNapoli; Shaker A Mousa
Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(4):341-5.
2007: Shaker A Mousa; Olga Goncharuk; Danny Miller
Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure.
Expert opinion on biological therapy 2007;7(5):617-25.
2007: Shaker A Mousa; Laura O'Connor; Toby G Rossman; Eric Block
Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds.
Carcinogenesis 2007;28(5):962-7.
2007: Shaker A Mousa; Sarfraz Ahmad
Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
American journal of hematology 2007;82(4):276-82.
2007: Saravanababu Murugesan; Shaker A Mousa; Laura J O'connor; David W Lincoln; Robert J Linhardt
Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis.
FEBS letters 2007;581(6):1157-60.
2007: Dhruba J Bharali; Shaker A Mousa; Yasmin Thanavala
Micro- and nanoparticle-based vaccines for hepatitis B.
Advances in experimental medicine and biology 2007;601():415-21.
2007: Shaker A Mousa
In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(1):55-60.
2006: Shaker A Mousa; Robert J Linhardt; John L Francis; Ali Amirkhosravi
Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Thrombosis and haemostasis 2006;96(6):816-21.
2006: Saravanababu Murugesan; Shaker A Mousa; Aravind Vijayaraghavan; Pulickel M Ajayan; Robert J Linhardt
Ionic liquid-derived blood-compatible composite membranes for kidney dialysis.
Journal of biomedical materials research. Part B, Applied biomaterials 2006;79(2):298-304.
2006: Shaker A Mousa; X Feng; J Xie; Y Du; Y Hua; H He; Laura O'Connor; R J Linhardt
Synthetic oligosaccharide stimulates and stabilizes angiogenesis: structure-function relationships and potential mechanisms.
Journal of cardiovascular pharmacology 2006;48(2):6-13.
2006: Faith B Davis; Heng-Yuan Tang; Ai Shih; Travis Keating; Lawrence Lansing; Aleck Hercbergs; Robert A Fenstermaker; Ahmed Mousa; Shaker A Mousa; Paul J Davis; Hung-Yun Lin
Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells.
Cancer research 2006;66(14):7270-5.
2006: Fuming Zhang; Peilong Sun; Eva Muñoz; Lianli Chi; Shinobu Sakai; Toshihiko Toida; Haifeng Zhang; Shaker A Mousa; Robert J Linhardt
Microscale isolation and analysis of heparin from plasma using an anion-exchange spin column.
Analytical biochemistry 2006;353(2):284-6.
2006: Shaker A Mousa
Role of current and emerging antithrombotics in thrombosis and cancer.
Drugs of today (Barcelona, Spain : 1998) 2006;42(5):331-50.
2006: Sarah Mousa; Shaker A Mousa
Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer.
Journal of cellular biochemistry 2006;97(6):1370-8.
2006: Saravanababu Murugesan; Tae-Joon Park; Hoichang Yang; Shaker A Mousa; Robert J Linhardt
Blood compatible carbon nanotubes--nano-based neoproteoglycans.
Langmuir : the ACS journal of surfaces and colloids 2006;22(8):3461-3.
2006: Shaker A Mousa; Laura O'Connor; Faith B Davis; Paul J Davis
Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated.
Endocrinology 2006;147(4):1602-7.
2006: Shaker A Mousa
Role of current and emerging antithrombotics in thrombosis and cancer.
Timely topics in medicine. Cardiovascular diseases 2006;10():E19.
2005: Lakshman R Sehgal; Jonathan Wong; Jie He; Trisha Wood; Ippei Takagi; Mohamed Mohamed Eldibany; Joseph A Caprini; Shaker A Mousa
Novel in vitro perfusion model to study the interaction between coagulation and blood-borne metastasis.
Journal of cellular biochemistry 2005;96(4):700-8.
2005: Jawed Fareed; Omer Iqbal; Helena Nader; Shaker A Mousa; Rakesh Wahi; Erwin Coyne; Rodger L Bick
Generic low molecular weight heparins: a significant dilemma.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2005;11(4):363-6.
2005: Shaker A Mousa; Laura O'Connor; Joel J Bergh; Faith B Davis; Thomas S Scanlan; Paul J Davis
The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin.
Journal of cardiovascular pharmacology 2005;46(3):356-60.
2005: Joel J Bergh; Hung-Yun Lin; Lawrence Lansing; Seema N Mohamed; Faith B Davis; Shaker A Mousa; Paul J Davis
Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis.
Endocrinology 2005;146(7):2864-71.
2005: Shaker A Mousa
Anti-thrombotics in thrombosis and cancer.
Future oncology (London, England) 2005;1(3):395-403.
2005: Shaker A Mousa
Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species.
Journal of cardiovascular pharmacology 2005;45(5):462-7.
2005: Shaker A Mousa
Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationship.
Journal of cellular biochemistry 2005;95(1):95-8.
2005: Sheila G West; Kirsten F Hilpert; Vijaya Juturu; Peter L Bordi; Johanna W Lampe; Shaker A Mousa; Penny M Kris-Etherton
Effects of including soy protein in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone replacement therapy.
Journal of women's health (2002) 2005;14(3):253-62.
2005: Shaker A Mousa; Jeffrey M Bozarth; Dietmar Seiffert; Giora Z Feuerstein
Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2005;16(3):165-71.
2005: Shaker A Mousa; Seema Mohamed
Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138.
Journal of cardiovascular pharmacology 2005;45(2):109-13.
2005: Shaker A Mousa; Hikmat N Abdel-Razeq
Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?
Cardiovascular drug reviews 2005;23(4):331-44.
2005: Ahmed S Mousa; Shaker A Mousa
Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53.
Nutrition and cancer 2005;53(1):104-10.
2005: Sarah S Mousa; Shaymaa S Mousa; Shaker A Mousa
Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane model.
Nutrition and cancer 2005;52(1):59-65.
2005: Shaker A Mousa; Seema Mohamed; Eric J Wexler; Janet S Kerr
Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
Anticancer research 2005;25(1A):197-206.
2005: Glenn L Stoller; Shaker A Mousa
Angiogenesis, choroidal neovascularization, and the coagulation system.
Retina (Philadelphia, Pa.) 2005;25(1):19-25.
2004: Syed Hamid Ali; Amy L O'Donnell; Seema Mohamed; Shaker A Mousa; Paresh Dandona
Overexpression of estrogen receptor-alpha in the endometrial carcinoma cell line Ishikawa: inhibition of growth and angiogenic factors.
Gynecologic oncology 2004;95(3):637-45.
2004: Shaker A Mousa; Seema Mohamed
Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy.
Oncology reports 2004;12(4):683-8.
2004: Shaker A Mousa; S Mohamed
Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
Thrombosis and haemostasis 2004;92(3):627-33.
2004: Parag Pawar; Pyong Kyun Shin; Shaker A Mousa; Julia M Ross; Konstantinos Konstantopoulos
Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(2):1258-65.
2004: Faith B Davis; Shaker A Mousa; Laura O'Connor; Seema Mohamed; Hung-Yun Lin; H James Cao; Paul J Davis
Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface.
Circulation research 2004;94(11):1500-6.
2004: Shaker A Mousa
Low-molecular-weight heparin in thrombosis and cancer.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():25-30.
2004: Joanne M Smallheer; Carolyn A Weigelt; Francis J Woerner; Jennifer S Wells; Wayne F Daneker; Shaker A Mousa; Ruth R Wexler; Prabhakar K Jadhav
Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.
Bioorganic & medicinal chemistry letters 2004;14(2):383-7.
2004: Tracy Shahan; Derrick Grant; Mason Tootell; Zahra Ziaie; Nobuko Ohno; Shaker A Mousa; Siema Mohamad; Horace M DeLisser; Nicholas Kefalides
Oncothanin, a peptide from the alpha3 chain of type IV collagen, modifies endothelial cell function and inhibits angiogenesis.
Connective tissue research 2004;45(3):151-63.
2004: Shaker A Mousa
Low-molecular-weight heparins in thrombosis and cancer: emerging links.
Cardiovascular drug reviews 2004;22(2):121-34.
2004: Shaker A Mousa; Ahmed S Mousa
Angiogenesis inhibitors: current & future directions.
Current pharmaceutical design 2004;10(1):1-9.
2004: Hikmat N Abdel-Razeq; mohamad qari; Jorgen Kristensen; Hussein Alizeidah; Faisal Al-Sayegh; Mahmoud Marashi; Abdulaziz Alzeer; Omar Al-Amoudi; Hatem Qutub; Abdel-Aziz Al-Humiadi; Steen Husted; Shaker A Mousa
Guidelines for diagnosis and treatment of deep venous thrombosis and pulmonary embolism.
Methods in molecular medicine 2004;93():267-92.
2004: Shaker A Mousa
Oral thrombin inhibitor ximelagatran.
Methods in molecular medicine 2004;93():247-51.
2004: Shaker A Mousa
Arixtra (fondaparinux sodium).
Methods in molecular medicine 2004;93():239-46.
2004: Shaker A Mousa
Cell adhesion molecules: potential therapeutic and diagnostic implications.
Methods in molecular medicine 2004;93():157-74.
2004: Shaker A Mousa; Jawed Fareed; Omer Iqbal; Brigitte Kaiser
Tissue factor pathway inhibitor in thrombosis and beyond.
Methods in molecular medicine 2004;93():133-55.
2004: Shaker A Mousa
Tissue factor/VIIa in thrombosis and cancer.
Methods in molecular medicine 2004;93():119-32.
2004: Shaker A Mousa
Are low molecular weight heparins the same?
Methods in molecular medicine 2004;93():49-59.
2004: Shaker A Mousa
Heparin and low molecular weight heparin in thrombosis, cancer, and inflammatory diseases.
Methods in molecular medicine 2004;93():35-48.
2004: Owen J T McCarty; James P Abulencia; Shaker A Mousa; Konstantinos Konstantopoulos
Evaluation of platelet antagonists in in vitro flow models of thrombosis.
Methods in molecular medicine 2004;93():21-34.
2004: Omer Iqbal; Shaker A Mousa
Antiplatelet, anticoagulant, and thrombolytic drug interactions.
Methods in molecular medicine 2004;93():9-20.
2004: Shaker A Mousa
Highlights of latest advances in antithrombotics.
Methods in molecular medicine 2004;93():1-7.
2003: Meghna U Naik; Shaker A Mousa; Charles A Parkos; Ulhas P Naik
Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex.
Blood 2003;102(6):2108-14.
2003: Ali Amirkhosravi; Shaker A Mousa; Mildred Amaya; Susan Blaydes; Hina Desai; Todd Meyer; John L Francis
Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454.
Thrombosis and haemostasis 2003;90(3):549-54.
2003: Ali Amirkhosravi; Shaker A Mousa; Mildred Amaya; John L Francis
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Journal of thrombosis and haemostasis : JTH 2003;1(9):1972-6.
2003: Shaker A Mousa
Antithrombotics in thrombosis and cancer.
Expert review of cardiovascular therapy 2003;1(2):283-91.
2003: Shaker A Mousa; Jeffrey M Bozarth; Jeffrey S Barrett
Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.
Journal of clinical pharmacology 2003;43(7):727-34.
2003: Cezary Marcinkiewicz; Paul H Weinreb; Juan J Calvete; Dariusz G Kisiel; Shaker A Mousa; George P Tuszynski; Roy R Lobb
Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo.
Cancer research 2003;63(9):2020-3.
2003: mohamad qari; Hikmat N Abdel-Razeq; Abdulaziz Alzeer; Hussain Alizadeh; Jorgen Kristensen; Faisal al-Sayegh; Hatem Qutub; Mahmoud Marashi; Steen Husted; Shaker A Mousa
Recent advances in the diagnosis and treatment of deep vein thrombosis: a regional consensus.
Current opinion in investigational drugs (London, England : 2000) 2003;4(3):309-15.
2003: Shaker A Mousa
alphav Vitronectin receptors in vascular-mediated disorders.
Medicinal research reviews 2003;23(2):190-9.
2003: Shaker A Mousa
Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Current pharmaceutical design 2003;9(28):2317-22.
2003: Robert W Colman; Robin A Pixley; Irma M Sainz; J S Song; Irma Isordia-Salas; S N Muhamed; J A Powell; Shaker A Mousa
Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen.
Journal of thrombosis and haemostasis : JTH 2003;1(1):164-70.
2002: Janet S Kerr; Andrew M Slee; Shaker A Mousa
The alpha v integrin antagonists as novel anticancer agents: an update.
Expert opinion on investigational drugs 2002;11(12):1765-74.
2002: Shaker A Mousa
Vitronectin receptors in vascular disorders.
Current opinion in investigational drugs (London, England : 2000) 2002;3(8):1191-5.
2002: Shaker A Mousa
Heparin and low molecular weight heparin in thrombosis and beyond.
Current opinion in investigational drugs (London, England : 2000) 2002;3(8):1181-6.
2002: Shaker A Mousa
Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications.
Current opinion in chemical biology 2002;6(4):534-41.
2002: Alexandre Caron; Jean-François Théorêt; Shaker A Mousa; Yahye Merhi
Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
Journal of cardiovascular pharmacology 2002;40(2):296-306.
2002: Shaker A Mousa; Mark S Forsythe; Jeffrey M Bozarth
Differential efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet/fibrin-mediated clot dynamics under different conditions using thrombelastography: the critical need for anticoagulant.
Coronary artery disease 2002;13(4):243-8.
2002: Shaker A Mousa; Omar Iqbal; Jawed Fareed
Antithrombotics and thrombolytics in stroke.
Current opinion in investigational drugs (London, England : 2000) 2002;3(6):878-85.
2002: Shaker A Mousa
Anticoagulants in thrombosis and cancer: the missing link.
Expert review of anticancer therapy 2002;2(2):227-33.
2002: Shaker A Mousa; James P Abulencia; Owen J T McCarty; Nancy A Turner; Konstantinos Konstantopoulos
Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Journal of cardiovascular pharmacology 2002;39(4):552-60.
2002: Shaker A Mousa
Anticoagulants in thrombosis and cancer: the missing link.
Seminars in thrombosis and hemostasis 2002;28(1):45-52.
2002: Shaker A Mousa
The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
Cardiovascular drug reviews 2002;20(3):199-216.
2002: Selim Elhadj; Shaker A Mousa; Kimberly Forsten-Williams
Chronic pulsatile shear stress impacts synthesis of proteoglycans by endothelial cells: effect on platelet aggregation and coagulation.
Journal of cellular biochemistry 2002;86(2):239-50.
2002: Eric Dupont; Pierre Falardeau; Shaker A Mousa; Violetta Dimitriadou; Marie-Claude Pepin; Taiqi Wang; Moulay A Alaoui-Jamali
Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue.
Clinical & experimental metastasis 2002;19(2):145-53.
2001: Thais M Sielecki; J Liu; Shaker A Mousa; Adrienne L Racanelli; E A Hausner; Ruth R Wexler; Richard E Olson
Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists.
Bioorganic & medicinal chemistry letters 2001;11(16):2201-4.
2001: Konstantinos Konstantopoulos; Shaker A Mousa
Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Current opinion in investigational drugs (London, England : 2000) 2001;2(8):1086-92.
2001: Syed Hamid Ali; Amy L O'Donnell; D Balu; M B Pohl; M J Seyler; S Mohamed; Shaker A Mousa; Paresh Dandona
High levels of oestrogen receptor-alpha in tumorigenesis: inhibition of cell growth and angiogenic factors.
Cell proliferation 2001;34(4):223-31.
2001: Shaker A Mousa; Jeffrey M Bozarth; U P Naik; AM Slee
Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
British journal of pharmacology 2001;133(3):331-6.
2001: M Wilson; R Blum; P Dandona; Shaker A Mousa
Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecule and inflammatory markers: a model of human diseases.
Clinical and experimental pharmacology & physiology 2001;28(5-6):376-80.
2001: Janet S Kerr; Shaker A Mousa; Andrew M Slee
Alpha(v)beta(3) integrin in angiogenesis and restenosis.
Drug news & perspectives 2001;14(3):143-50.
2001: Joel S Bennett; Shaker A Mousa
Platelet function inhibitors in the Year 2000.
Thrombosis and haemostasis 2001;85(3):395-400.
2001: James P Abulencia; N Tien; Owen J T McCarty; D Plymire; Shaker A Mousa; Konstantinos Konstantopoulos
Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(1):149-56.
2000: Syed Hamid Ali; Amy L O'Donnell; D Balu; M B Pohl; M J Seyler; S Mohamed; Shaker A Mousa; Paresh Dandona
Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis.
Cancer research 2000;60(24):7094-8.
2000: Shaker A Mousa; Mark S Forsythe; Jeffrey M Bozarth; F Jin; P N Confalone
Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
Coronary artery disease 2000;11(7):563-70.
2000: J A Powell; S N Mohamed; J S Kerr; Shaker A Mousa
Antiangiogenesis efficacy of nitric oxide donors.
Journal of cellular biochemistry 2000;80(1):104-14.
2000: D J Suich; Shaker A Mousa; G Singh; G Liapakis; Terry Reisine; William F DeGrado
Template-constrained cyclic peptide analogues of somatostatin: subtype-selective binding to somatostatin receptors and antiangiogenic activity.
Bioorganic & medicinal chemistry 2000;8(9):2229-41.
2000: Shaker A Mousa; Jeffrey M Bozarth; Mark S Forsythe; AM Slee
Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Cardiovascular research 2000;47(4):819-26.
2000: Owen J T McCarty; Shaker A Mousa; P F Bray; Konstantinos Konstantopoulos
Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions.
Blood 2000;96(5):1789-97.
2000: O Helluin; C Chan; Gaston Vilaire; Shaker A Mousa; William F DeGrado; Joel S Bennett
The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin.
The Journal of biological chemistry 2000;275(24):18337-43.
2000: H L Walton; MH Corjay; S N Mohamed; Shaker A Mousa; L D Santomenna; Thomas M Reilly
Hypoxia induces differential expression of the integrin receptors alpha(vbeta3) and alpha(vbeta5) in cultured human endothelial cells.
Journal of cellular biochemistry 2000;78(4):674-80.
2000: Janet S Kerr; Andrew M Slee; Shaker A Mousa
Small molecule alpha(v) integrin antagonists: novel anticancer agents.
Expert opinion on investigational drugs 2000;9(6):1271-9.
2000: Carter Van Waes; I Enamorado-Ayala; D Hecht; L Sulica; Z Chen; Douglas G Batt; Shaker A Mousa
Effects of the novel alphav integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8.
International journal of oncology 2000;16(6):1189-95.
2000: Thais M Sielecki; John Wityak; J Liu; Shaker A Mousa; MJ Thoolen; Ruth R Wexler; Richard E Olson
Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists.
Bioorganic & medicinal chemistry letters 2000;10(5):449-52.
2000: Robert W Colman; Bradford A Jameson; Yingzhang Lin; D Johnson; Shaker A Mousa
Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.
Blood 2000;95(2):543-50.
2000: Douglas G Batt; Joseph J Petraitis; Gregory C Houghton; Dilip P Modi; Gary A Cain; MH Corjay; Shaker A Mousa; P J Bouchard; Mark S Forsythe; P P Harlow; Frank Barbera; S M Spitz; Ruth R Wexler; Prabhakar K Jadhav
Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3).
Journal of medicinal chemistry 2000;43(1):41-58.
2000: William Pitts; John Wityak; Joanne M Smallheer; A E Tobin; JW Jetter; J S Buynitsky; P P Harlow; K A Solomon; MH Corjay; Shaker A Mousa; Ruth R Wexler; Prabhakar K Jadhav
Isoxazolines as potent antagonists of the integrin alpha(v)beta(3).
Journal of medicinal chemistry 2000;43(1):27-40.
2000: Shaker A Mousa
Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
Seminars in thrombosis and hemostasis 2000;26 Suppl 1():39-46.
1999: Shaker A Mousa; R Kapil; D X Mu
Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(10):2535-41.
1999: Jeffrey S Barrett; J Yu; RP Kapil; P Padovani; F Brown; William Ebling; MH Corjay; Thomas M Reilly; Jeffrey M Bozarth; Shaker A Mousa; Henry J Pieniaszek
Disposition and exposure of the fibrinogen receptor antagonist XV459 on alphaIIBbeta3 binding sites in the guinea pig.
Biopharmaceutics & drug disposition 1999;20(6):309-18.
1999: Shaker A Mousa; W Lorelli; Peter A Campochiaro
Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells.
Journal of cellular biochemistry 1999;74(1):135-43.
1999: Richard E Olson; Thais M Sielecki; John Wityak; Donald J P Pinto; Douglas G Batt; William E Frietze; J Liu; AE Tobin; Michael J Orwat; S V Di Meo; Gregory C Houghton; G K Lalka; Shaker A Mousa; Adrienne L Racanelli; E A Hausner; RP Kapil; S R Rabel; MJ Thoolen; Thomas M Reilly; PS Anderson; Ruth R Wexler
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
Journal of medicinal chemistry 1999;42(7):1178-92.
1999: AL Rockwell; M Rafalski; William Pitts; Douglas G Batt; Joseph J Petraitis; WF DeGrado; Shaker A Mousa; Prabhakar K Jadhav
Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of alphavbeta3 antagonists lead compounds.
Bioorganic & medicinal chemistry letters 1999;9(7):937-42.
1999: Shaker A Mousa; W Lorelli; S Mohamed; Douglas G Batt; Prabhakar K Jadhav; Thomas M Reilly
Alphavbeta3 integrin binding affinity and specificity of SM256 in various species.
Journal of cardiovascular pharmacology 1999;33(4):641-6.
1999: Janet S Kerr; RS Wexler; Shaker A Mousa; CS Robinson; Eric J Wexler; Seema Mohamed; M E Voss; J J Devenny; P M Czerniak; A Gudzelak; Andrew M Slee
Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors.
Anticancer research 1999;19(2A):959-68.
1999: John Wityak; A E Tobin; Shaker A Mousa; Ruth R Wexler; Richard E Olson
Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate.
Bioorganic & medicinal chemistry letters 1999;9(2):123-6.
1998: Chu-Biao Xue; John Roderick; Shaker A Mousa; Richard E Olson; WF DeGrado
Synthesis and antiplatelet effects of an isoxazole series of glycoprotein IIb/IIIa antagonists.
Bioorganic & medicinal chemistry letters 1998;8(24):3499-504.
1998: Halina Machelska; PJ Cabot; Shaker A Mousa; Q Zhang; Christoph Stein
Pain control in inflammation governed by selectins.
Nature medicine 1998;4(12):1425-8.
1998: Shaker A Mousa; Mark S Forsythe; Jeffrey M Bozarth; A Youssef; John Wityak; R Olson; Thais M Sielecki
XV454, a novel nonpeptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet alpha(IIb)beta3-binding kinetics to c7E3.
Journal of cardiovascular pharmacology 1998;32(5):736-44.
1998: Shaker A Mousa; D X Mu; M A Hussain
Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755.
Thrombosis research 1998;92(3):115-24.
1998: Shaker A Mousa; Jeffrey M Bozarth; W Lorelli; Mark S Forsythe; MJ Thoolen; AM Slee; Thomas M Reilly; P A Friedman
Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1277-84.
1998: Shaker A Mousa; Richard E Olson; Jeffrey M Bozarth; W Lorelli; Mark S Forsythe; Adrienne L Racanelli; S Gibbs; K Schlingman; T Bozarth; RP Kapil; John Wityak; Thais M Sielecki; Ruth R Wexler; MJ Thoolen; AM Slee; Thomas M Reilly; PS Anderson; P A Friedman
Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
Journal of cardiovascular pharmacology 1998;32(2):169-76.
1998: Donna L Pedicord; Beth E Thomas; Shaker A Mousa; ira dicker
Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
Thrombosis research 1998;90(6):247-58.
1998: Shaker A Mousa; Jeffrey M Bozarth; A Youssef; B Levine
Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates.
Thrombosis research 1998;89(5):217-25.
1998: Shaker A Mousa; Mark S Forsythe; John Wityak; Jeffrey M Bozarth; D X Mu
Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
Journal of cardiovascular pharmacology 1998;31(3):441-8.
1998: Shaker A Mousa; Jeffrey M Bozarth; S Edwards; T Carroll; J Barrett
Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis.
Coronary artery disease 1998;9(2-3):131-41.
1997: M A Hussain; BJ Aungst; R Kapil; Shaker A Mousa
Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability.
Journal of pharmaceutical sciences 1997;86(12):1358-60.
1997: P W Tsao; Mark S Forsythe; Shaker A Mousa
Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728.
Thrombosis research 1997;88(2):137-46.
1997: Chu-Biao Xue; John Wityak; Thais M Sielecki; Donald J P Pinto; Douglas G Batt; Gary A Cain; M Sworin; AL Rockwell; John Roderick; Shuaige Wang; Michael J Orwat; William E Frietze; Lori L Bostrom; J Liu; C Anne Higley; F W Rankin; AE Tobin; G Emmett; G K Lalka; J Y Sze; S V Di Meo; Shaker A Mousa; MJ Thoolen; Adrienne L Racanelli; Richard E Olson
Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.
Journal of medicinal chemistry 1997;40(13):2064-84.
1997: R P Kapil; T A Emm; Shaker A Mousa; P K Padovani; C Y Quon; G N Lam
Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogs.
Thrombosis research 1997;86(3):221-32.
1997: Chu-Biao Xue; John Roderick; S Jackson; M Rafalski; AL Rockwell; Shaker A Mousa; Richard E Olson; WF DeGrado
Design, synthesis, and in vitro activities of benzamide-core glycoprotein IIb/IIIa antagonists: 2,3-diaminopropionic acid derivatives as surrogates of aspartic acid.
Bioorganic & medicinal chemistry 1997;5(4):693-705.
1997: Joel S Bennett; C Chan; Gaston Vilaire; Shaker A Mousa; William F DeGrado
Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin.
The Journal of biological chemistry 1997;272(13):8137-40.
1997: John Wityak; Thais M Sielecki; Donald J P Pinto; G Emmett; J Y Sze; J Liu; AE Tobin; Shuaige Wang; B Jiang; P Ma; Shaker A Mousa; Ruth R Wexler; Richard E Olson
Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.
Journal of medicinal chemistry 1997;40(1):50-60.
1996: Shaker A Mousa; Mark S Forsythe; W Lorelli; Jeffrey M Bozarth; Chu-Biao Xue; John Wityak; Thais M Sielecki; Richard E Olson; W DeGrado; R Kapil; M Hussain; Ruth R Wexler; MJ Thoolen; Thomas M Reilly
Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.
Coronary artery disease 1996;7(10):767-74.
1996: Shaker A Mousa; W F DeGrado; D X Mu; R P Kapil; Benedict R Lucchesi; Thomas M Reilly
Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
Circulation 1996;93(3):537-43.
1995: Thomas M Reilly; Shaker A Mousa; Adrienne L Racanelli; MJ Thoolen; S K Flint; Jeffrey M Bozarth; D X Mu; H L Walton
A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog.
Arteriosclerosis, thrombosis, and vascular biology 1995;15(12):2195-9.
1995: P W Tsao; Shaker A Mousa
Thrombospondin mediates calcium mobilization in fibroblasts via its Arg-Gly-Asp and carboxyl-terminal domains.
The Journal of biological chemistry 1995;270(40):23747-53.
1995: P W Tsao; Jeffrey M Bozarth; S A Jackson; Mark S Forsythe; S K Flint; Shaker A Mousa
Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide.
Thrombosis research 1995;77(6):543-56.
1994: Shaker A Mousa; Mark S Forsythe; M Diemer; Jeffrey M Bozarth; Thomas M Reilly
Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Coronary artery disease 1994;5(11):919-27.
1994: Shaker A Mousa; S Flint; W Lorelli; S Hassell; Jeffrey M Bozarth; W De Grado; Thomas M Reilly
Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs.
Thrombosis research 1994;76(2):109-19.
1994: Shaker A Mousa; W F De Grado; T M Reilly
Platelet GPIIb/IIIa antagonists: how safe is this antithrombotic approach?
The American journal of medicine 1994;96(3):300.
1994: Thomas M Reilly; Shaker A Mousa; R Seetharam; Adrienne L Racanelli
Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1994;5(1):73-81.
1994: Shaker A Mousa; Jeffrey M Bozarth; Mark S Forsythe; S M Jackson; A Leamy; M M Diemer; R P Kapil; Robert M Knabb; M C Mayo; S K Pierce
Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Circulation 1994;89(1):3-12.
1994: Shaker A Mousa; Jeffrey M Bozarth; Mark S Forsythe; P Tsao; L Pease; Thomas M Reilly
Role of platelet GpIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release.
Life sciences 1994;54(16):1155-62.
1994: K T O'Neil; W F DeGrado; Shaker A Mousa; N Ramachandran; R H Hoess
Identification of recognition sequences of adhesion molecules using phage display technology.
Methods in enzymology 1994;245():370-86.
1993: Thomas M Reilly; Mark S Forsythe; Adrienne L Racanelli; S M Spitz; H L Walton; Shaker A Mousa
Recombinant plasminogen activator inhibitor-1 protects platelets against the inhibitory effects of plasmin.
Thrombosis research 1993;71(1):61-8.
1993: Shaker A Mousa; Thomas M Reilly
Pharmacological blockade of platelet GPIIb/IIIa and the inherited disorders of the platelet GPIIb/IIIa (Glanzmann's thrombasthenia): how safe is this antithrombotic approach for both acute and chronic treatment of thromboembolic disorders? Brief communication.
Cardiology 1993;83(1-2):36-7.
1993: Shaker A Mousa; Mark S Forsythe; Jeffrey M Bozarth; Thomas M Reilly
Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1.
Cardiology 1993;83(5-6):367-73.
1993: Shaker A Mousa; Jeffrey M Bozarth; Mark S Forsythe; W Lorelli; MJ Thoolen; N Ramachandran; S Jackson; W De Grado; Thomas M Reilly
Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist.
Cardiology 1993;83(5-6):374-82.
1992: K T O'Neil; R H Hoess; S A Jackson; N S Ramachandran; Shaker A Mousa; W F DeGrado
Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library.
Proteins 1992;14(4):509-15.
1992: Thomas M Reilly; Robert M Knabb; S M Hassell; Jeffrey M Bozarth; Mark S Forsythe; M C Mayo; Adrienne L Racanelli; Shaker A Mousa
Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1992;3(5):513-7.
1992: Shaker A Mousa; G Patil; M C Mayo; T M Tong
Myocardial anti-ischemic characteristics of a novel class of beta-adrenoceptor blockers.
International journal of clinical pharmacology, therapy, and toxicology 1992;30(3):103-6.
1991: A T Chiu; Shaker A Mousa; L J Pease; W A Roscoe; Jeffrey M Bozarth; Thomas M Reilly; R D Smith; P B Timmermans
Inhibition of the thrombin-platelet reactions by DuP 714.
Biochemical and biophysical research communications 1991;179(3):1500-8.